血友病临床试验招募信息（全球在招）

这里汇总了全球正在招募患者的 血友病（国际通用名 hemophilia）新药临床试验，包含试验分期、招募状态、开展国家和研究团队联系方式，全部以中文呈现。数据实时来自全球最大的临床试验注册库 ClinicalTrials.gov。

正在招募的血友病新药试验

• A Gene Therapy Study of SPK-8011QQ in Adults With Severe or Moderately Severe Hemophilia A

  I 期 / II 期招募中美国NCT07226206

• Long-term Anticoagulation in a Patient With Severe Hemophilia A

  不适用招募中法国NCT07314983

• Severe Congenital Hemostatic Defects, Cerebral MIcrobleeds and COGnition

  不适用招募中法国NCT06090201

• SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors

  IV 期招募中美国NCT04647227

• A Study to Test a Medicine (Fitusiran) for Preventing Bleeds in People With Severe Hemophilia Who Previously Received Preventive Treatment With Emicizumab

  IV 期招募中美国中国台湾NCT06145373

• Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B

  III 期招募中美国AustriaBelgium法国NCT07080905

• Manual Therapy in Hemophilic Arthropathy of the Ankle

  不适用招募中西班牙NCT06816056

• A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B

  I 期 / II 期招募中美国澳大利亚Brazil加拿大NCT06379789

• Dynamics of the Anti-factor VIII Antibody Signature During Treatment With Emicizumab

  不适用招募中德国NCT05802836

• Gene Therapy for Hemophilia B Patients Aged 12-18 Years Old

  I 期招募中中国NCT05709288

• Study of Surgical Practices in Hemophilia A Patients Treated With Efanesoctocog Alfa (Altuvoct®)

  不适用招募中法国NCT07723560

• An Open-Label, Comparative Study of the Efficacy, Safety and Pharmacodynamics of Single Dose of ANB-002 in Patients With Hemophilia B

  III 期招募中RussiaThailandNCT06700096